# PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

> **NCT00313482** · PHASE2 · TERMINATED · sponsor: **Veeda Oncology** · enrollment: 35 (actual)

## Conditions studied

- Hormone Refractory Prostate Cancer

## Interventions

- **DRUG:** Sargramostim
- **DRUG:** Docetaxel
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00313482
- **Lead sponsor:** Veeda Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2012-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00313482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00313482, "PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00313482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*